Abstract
In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10). After 3 months, both treatments had similar effects on androgen levels, lipid profile, insulin sensitivity, and serum inflammatory markers, but flow-mediated dilatation increased by 69.0% in the metformin plus OC group while it remained unchanged in the OC group. CLINICAL TRIAL REGISTRATION NO: NCT00682890.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Publication types
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
MeSH terms
-
Analysis of Variance
-
Biomarkers / blood
-
Blood Glucose / drug effects
-
Contraceptives, Oral, Combined / administration & dosage*
-
Contraceptives, Oral, Hormonal / administration & dosage*
-
Double-Blind Method
-
Drug Combinations
-
Drug Therapy, Combination
-
Endothelium, Vascular / drug effects*
-
Endothelium, Vascular / physiopathology
-
Ethinyl Estradiol / administration & dosage*
-
Female
-
Gonadal Steroid Hormones / blood
-
Humans
-
Hypoglycemic Agents / administration & dosage*
-
Inflammation Mediators / blood
-
Insulin / blood
-
Insulin Resistance
-
Lipids / blood
-
Metformin / administration & dosage*
-
Norgestrel / administration & dosage
-
Norgestrel / analogs & derivatives*
-
Obesity / blood
-
Obesity / complications*
-
Obesity / physiopathology
-
Overweight / blood
-
Overweight / complications*
-
Overweight / physiopathology
-
Placebo Effect
-
Polycystic Ovary Syndrome / blood
-
Polycystic Ovary Syndrome / complications
-
Polycystic Ovary Syndrome / drug therapy*
-
Polycystic Ovary Syndrome / physiopathology
-
Time Factors
-
Treatment Outcome
-
Vasodilation / drug effects
-
Virginia
Substances
-
Biomarkers
-
Blood Glucose
-
Contraceptives, Oral, Combined
-
Contraceptives, Oral, Hormonal
-
Drug Combinations
-
Gonadal Steroid Hormones
-
Hypoglycemic Agents
-
Inflammation Mediators
-
Insulin
-
Lipids
-
norgestimate, ethinyl estradiol drug combination
-
Norgestrel
-
Ethinyl Estradiol
-
Metformin
Associated data
-
ClinicalTrials.gov/NCT00682890